secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001564590-21-056175
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrödinger Q3 revenue $29.9M (+16% YoY); net loss $35M vs $3.9M income; lowers drug discovery revenue guidance
--------------------------------------------------------------------------------

- Revenue $29.9M (+16% YoY); software revenue $24.3M (+6%), drug discovery $5.6M (up from $2.9M).
- Net loss $35.0M vs net income $3.9M in Q3 2020; operating expenses rose to $45.8M from $30.7M.
- Cash and marketable securities $600.2M as of Sep 30, 2021, down from $616.6M at Jun 30.
- Full-year drug discovery revenue guidance revised to $22-24M from $22-32M; software guidance maintained at $102-110M.
- Selected development candidate for CDC7 inhibitor; MALT1 IND submission expected H1 2022; pipeline expanded to five programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000156459021056175/0001564590-21-056175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000156459021056175/sdgr-8k_20211110.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-056175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer